This report provides a comprehensive financial analysis of GlaxoSmithKline PLC (GSK PLC), comparing its performance with competitor Johnson & Johnson across 2016 and 2017. It uses ratio analysis, including profitability ratios like return on capital employed and operating profit margin, as well as market value ratios such as earnings per share, to assess GSK's financial health. The report also explores budgetary techniques, focusing on zero-based budgeting, its benefits, and drawbacks. Additionally, it discusses performance measurement using the balanced scorecard approach and examines investment decisions. The analysis concludes with recommendations for investors, suggesting that GSK PLC is a more favorable investment option compared to Johnson & Johnson based on the financial data presented. Desklib provides this report as a study resource, among other solved assignments and past papers.
![[object Object]](/_next/static/media/star-bottom.7253800d.svg)
